Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases.
Siddharth SinghHerbert C HeienLindsey SangaralinghamNilay D ShahWilliam J SandbornPublished in: Digestive diseases and sciences (2021)
In an observational study of patients with IBD, no differences were observed in the risk of incident malignancy in patients treated with vedolizumab versus TNFα antagonists.